Multicentre Post-market Study of Ectoin® Inhalation Solution in Treatment of Asthma.

NACompletedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

January 13, 2023

Primary Completion Date

October 16, 2023

Study Completion Date

October 25, 2023

Conditions
Asthma
Interventions
DEVICE

Ectoin® Inhalation Solution

Ectoin Inhalation Solution (Class-IIa Medical Device Directive (MDD) legacy medical device) is an isotonic, aqueous solution containing Ectoin 1.3 % and sea salt 0.6%. It is used for moistening the lung epithelium by the Ectoin hydro complex and supports the barrier function of the lung epithelium. The inhalation solution can be administered with jet, mesh, and ultrasound nebulizers.

Trial Locations (5)

15-430

Site 5, Bialystok

20-095

Site 1, Lublin

61-578

Site 4, Poznan

35-612

Site 2, Rzeszów

04-314

Site 3, Warsaw

All Listed Sponsors
lead

Bitop AG

INDUSTRY